Japanese biotech firm Rakuten Medical plans expansion into international markets

AI-summarized · Neutrality-checked

Rakuten Medical CEO Minami Maeda announced plans to expand the Japanese biotech firm's photoimmunotherapy treatment, which uses the proprietary Alluminox platform and Akalux drug, into international markets including Singapore, Taiwan, Macau, and Saudi Arabia. The company, which is currently headquartered in San Diego and running Phase 3 U.S. clinical…

Sources and context

Know where. Know why.